Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report

Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report

Osimertinib has become the preferred first-line therapy for epidermal growth factor receptor (<i>EGFR)</i> mutation-positive metastatic non-small cell lung cancer (NSCLC) in recent years. Originally, it was approved for second-line treatment after epidermal growth factor receptor <i&g...

Full description

Bibliographic Details
Main Authors: Markus Falk, Stefanie Schatz, Fabian P. M. Reich, Stefanie Schmidt, Marco Galster, Markus Tiemann, Joachim H. Ficker, Wolfgang M. Brueckl
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Current Oncology
Subjects:
disease monitoring
<i>EGFR</i>
hybrid capture NGS
osimertinib
liquid biopsy
Online Access:https://www.mdpi.com/1718-7729/30/10/640

Internet

https://www.mdpi.com/1718-7729/30/10/640

Similar Items